Targeted and Personalized Therapy for Nonmelanoma Skin Cancers

  • Chantal C. Bachmann
  • Günther F. L. HofbauerEmail author


AK lesions are caused by chronic ultraviolet radiation exposure, and the presence of two or more AK lesions along with photodamage should raise consideration of a diagnosis of field cancerization. Treatment of AK and field cancerization should be driven by consideration of relevant patient, disease, and treatment factors, and appropriate treatment decisions will differ from patient to patient.


Chronic Lymphocytic Leukemia Basal Cell Carcinoma Actinic Keratosis Organ Transplant Recipient Invasive Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.





Actinic keratosis


5-Aminolevulinic acid




Basal cell carcinoma


Chronic lymphocytic leukemia


Calcineurin inhibitors such as cyclosporin A, tacrolimus




Cyclosporin A


Local skin reactions


Methyl aminolevulinate


Mycophenolate mofetil


Non-Hodgkin lymphoma


Nonmelanoma skin cancer


Organ transplant recipients


Photodynamic therapy


Randomized controlled trial


Swiss Registry of Actinic Keratosis Treatment


Salicylic acid


Squamous cell carcinoma






  1. 1.
    Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115(6):649–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22(3):189–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis – an update. Br J Dermatol. 2007;157 Suppl 2:18–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Lucas RM, McMichael AJ, Armstrong BK, Smith WT. Estimating the global disease burden due to ultraviolet radiation exposure. Int J Epidemiol. 2008;37(3):654–67.CrossRefPubMedGoogle Scholar
  5. 5.
    Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131(4):455–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167 Suppl 2:36–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998;37(9):677–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169(3):502–18.CrossRefPubMedGoogle Scholar
  10. 10.
    Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354(9180):723–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Ulrich C, Jürgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012;118(8):2128–37.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Endrizzi BT, Lee PK. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg. 2009;35(10):1567–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2011;25(4):541–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Hofbauer GF, Anliker M, Arnold A, et al. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly. 2009;139(29–30):407–15.PubMedGoogle Scholar
  16. 16.
    Peris K, Micantonio T, Piccolo D, Fargnoli MC. Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges. 2007;5(11):970–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Zalaudek I, Giacomel J, Schmid K, et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol. 2012;66(4):589–97.CrossRefPubMedGoogle Scholar
  18. 18.
    Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation. 2008;86(3):423–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol. 2006;86(1):25–8.PubMedGoogle Scholar
  20. 20.
    Chen SC, Hill ND, Veledar E, Swetter SM, Weinstock MA. Reliability of quantification measures of actinic keratosis. Br J Dermatol. 2013;169(6):1219–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Elliott R. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy. 2009;14(1):58–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol. 2003;139(4):451–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329(16):1147–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, et al. Assessing physicians’ preferences on skin cancer treatment in Europe. Br J Dermatol. 2012;167 Suppl 2:29–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43(9):687–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Zouboulis CC. Cryosurgery in dermatology. Eur J Dermatol. 1998;8(7):466–74.PubMedGoogle Scholar
  27. 27.
    Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26(8):728–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157 Suppl 2:34–40.CrossRefPubMedGoogle Scholar
  29. 29.
    Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70(2 Suppl):30–6.PubMedGoogle Scholar
  30. 30.
    Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990–1000.CrossRefPubMedGoogle Scholar
  31. 31.
    Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70(6):335–9.PubMedGoogle Scholar
  32. 32.
    Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22–9.PubMedGoogle Scholar
  33. 33.
    Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Rundhaug JE, Fischer SM. Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol. 2008;84(2):322–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156 Suppl 3:25–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709–13.CrossRefPubMedGoogle Scholar
  37. 37.
    Ulrich C, Hackethal M, Ulrich M, et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol. 2007;156 Suppl 3:40–2.CrossRefPubMedGoogle Scholar
  38. 38.
    Ulrich C, Johannsen A, Röwert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20(4):482–8.PubMedGoogle Scholar
  39. 39.
    Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141(4):467–73.CrossRefPubMedGoogle Scholar
  40. 40.
    Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547–55.CrossRefPubMedGoogle Scholar
  41. 41.
    Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg. 2005;31(6):659–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57(2):265–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157(1):133–41.CrossRefPubMedGoogle Scholar
  44. 44.
    Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol. 2004;45(2):123–4.CrossRefPubMedGoogle Scholar
  45. 45.
    Patel U, Mark NM, Machler BC, Levine VJ. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol. 2011;164(3):670–2.PubMedGoogle Scholar
  46. 46.
    Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol. 2006;45(12):1464–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Wolfe CM, Tafuri N, Hatfield K. Exacerbation of myasthenia gravis during imiquimod treatment. J Drugs Dermatol. 2007;6(7):745–6.PubMedGoogle Scholar
  48. 48.
    Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582–90.CrossRefPubMedGoogle Scholar
  49. 49.
    Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62(4):573–81.CrossRefPubMedGoogle Scholar
  50. 50.
    Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001;48(6):751–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Fujisawa H, Kondo S, Wang B, Shivji GM, Sauder DN. The role of CD4 molecules in the induction phase of contact hypersensitivity cytokine profiles in the skin and lymph nodes. Immunology. 1996;89(2):250–5.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205–10.CrossRefPubMedGoogle Scholar
  53. 53.
    Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486–93.CrossRefPubMedGoogle Scholar
  54. 54.
    Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–70.CrossRefPubMedGoogle Scholar
  56. 56.
    Jarret M, Katsamas J, Cawkill K, Henderson L, Welburn P, editors. A pharmacokinetic study using a highly sensitive and specific method to determine systemic exposure of ingenol mebutate and its two main metabolites, PEP 015 and PEP 025 in human whole blood after topical administration. Am Acad Dermatol. 2013;AB 156.Google Scholar
  57. 57.
    Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125–43.CrossRefPubMedGoogle Scholar
  58. 58.
    Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146(4):552–67.CrossRefPubMedGoogle Scholar
  59. 59.
    Morton CA, McKenna KE, Rhodes LE, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159(6):1245–66.CrossRefPubMedGoogle Scholar
  60. 60.
    Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(5):536–44.CrossRefPubMedGoogle Scholar
  61. 61.
    Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 2: emerging indications–field cancerization, photorejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol. 2013;27(6):672–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45(1):96–104.CrossRefPubMedGoogle Scholar
  63. 63.
    Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140(1):41–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85(5):424–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Szeimies RM, Torezan L, Niwa A, et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol. 2012;167(1):150–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Wiegell SR, Wulf HC, Szeimies RM, et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol. 2012;26(6):673–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol. 2008;158(4):740–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol. 2009;160(6):1308–14.CrossRefPubMedGoogle Scholar
  69. 69.
    Wiegell SR, Fabricius S, Stender IM, et al. A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol. 2011;164(5):1083–90.CrossRefPubMedGoogle Scholar
  70. 70.
    Barta U, Gräfe T, Wollina U. Radiation therapy for extensive actinic keratosis. J Eur Acad Dermatol Venereol. 2000;14(4):293–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Dinehart SM, Graham M, Maners A. Radiation therapy for widespread actinic keratoses. J Clin Aesthet Dermatol. 2011;4(7):47–50.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Pipitone MA, Gloster HM. Superficial squamous cell carcinomas and extensive actinic keratoses of the scalp treated with radiation therapy. Dermatol Surg. 2006;32(5):756–9.PubMedGoogle Scholar
  73. 73.
    Caccialanza M, Piccinno R, Beretta M, Gnecchi L. Results and side effects of dermatologic radiotherapy: a retrospective study of irradiated cutaneous epithelial neoplasms. J Am Acad Dermatol. 1999;41(4):589–94.PubMedGoogle Scholar
  74. 74.
    Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg. 1987;80(1):47–54.CrossRefPubMedGoogle Scholar
  75. 75.
    van Zuuren EJ, Posma AN, Scholtens RE, Vermeer BJ, van der Woude FJ, Bouwes Bavinck JN. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol. 1994;31(5 Pt 1):760–4.CrossRefPubMedGoogle Scholar
  76. 76.
    Weinstock MA, Bingham SF, Digiovanna JJ, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132(6):1583–90.CrossRefPubMedGoogle Scholar
  77. 77.
    Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006;142(8):976–82.CrossRefPubMedGoogle Scholar
  78. 78.
    Serra-Guillén C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol. 2012;66(4):e131–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Galitzer BI. Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm. J Drugs Dermatol. 2011;10(10):1124–32.PubMedGoogle Scholar
  80. 80.
    Martin G. Prospective case-based assessment of sequential therapy with topical fluorouracil cream 0.5% and ALA-PDT for the treatment of actinic keratosis. J Drugs Dermatol. 2011;10(4):372–8.PubMedGoogle Scholar
  81. 81.
    Van der Geer S, Krekels GA. Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. J Dermatolog Treat. 2009;20(5):259–65.CrossRefPubMedGoogle Scholar
  82. 82.
    Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9(9):1101–8.PubMedGoogle Scholar
  83. 83.
    Tan JK, Thomas DR, Poulin Y, Maddin F, Tang J. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11(6):195–201.PubMedGoogle Scholar
  84. 84.
    Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7(7):669–73.PubMedGoogle Scholar
  85. 85.
    Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140(7):813–6.CrossRefPubMedGoogle Scholar
  86. 86.
    Website Cg. A sequential treatment regimen of cryotherapy and Picato® for the treatment of actinic keratosis on the face and scalp. Accessed 4 Jun 2013.
  87. 87.
    Berman B, Goldenberg G, Hanke CW, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13(2):154–60.PubMedGoogle Scholar
  88. 88.
    Ondo AL, Padilla RS, Miedler JD, et al. Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study. Dermatol Surg. 2012;38(9):1469–76.CrossRefPubMedGoogle Scholar
  89. 89.
    Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol. 2007;6(8):778–81.PubMedGoogle Scholar
  90. 90.
    Ulrich C, Christophers E, Sterry W, Meyer T, Stockfleth E. Skin diseases in organ transplant patients. Hautarzt. 2002;53(8):524–33.CrossRefPubMedGoogle Scholar
  91. 91.
    Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–39.CrossRefPubMedGoogle Scholar
  93. 93.
    Hofbauer GF, Attard NR, Harwood CA, et al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant. 2012;12(1):218–25.CrossRefPubMedGoogle Scholar
  94. 94.
    Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2 Pt 1):177–86.CrossRefPubMedGoogle Scholar
  95. 95.
    Tessari G, Girolomoni G. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg. 2012;38(10):1622–30.CrossRefPubMedGoogle Scholar
  96. 96.
    Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157 Suppl 2:25–31.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Chantal C. Bachmann
    • 1
  • Günther F. L. Hofbauer
    • 1
    Email author
  1. 1.Department of DermatologyUniversitätsSpital ZürichZürichSwitzerland

Personalised recommendations